Abstract
Background: On June 1, 2021, Vermont repealed all criminal penalties for possessing 224 milligrams or less of buprenorphine. We examined the potential impact of decriminalization with a survey of Vermont clinicians who prescribed buprenorphine within the past year. Methods: All 638 Vermont clinicians with a waiver to prescribe buprenorphine were emailed the survey by Vermont Department of Health; 117 responded. We estimated the prevalence of the following four outcomes, for all responding clinicians and stratified by clinician demographics and practice characteristics: awareness of decriminalization, beliefs about the effects of decriminalization, support for decriminalization, and changes in practice resulting from decriminalization. Results: 72 (62%) prescribers correctly stated that Vermont does not have criminal penalties for buprenorphine possession. 107 (91%) support decriminalization. 56 (48%) believe that, because buprenorphine is decriminalized, their patients are more likely to give, sell, or trade the buprenorphine that is prescribed to them to someone else. However, only 5 providers (4%) said they now prescribe to fewer patients. Conclusion: The great majority of Vermont clinicians who prescribe buprenorphine support its decriminalization and have not changed their prescribing practices because of decriminalization.
Original language | English (US) |
---|---|
Pages (from-to) | 150-153 |
Number of pages | 4 |
Journal | Substance Use and Misuse |
Volume | 59 |
Issue number | 1 |
DOIs |
|
State | Published - 2024 |
Keywords
- Buprenorphine
- drug decriminalization
- overdose
- state policy
- survey
ASJC Scopus subject areas
- Medicine (miscellaneous)
- Health(social science)
- Public Health, Environmental and Occupational Health
- Psychiatry and Mental health